DN

Dhruv Nileshbhai Patvana

Active Director Designated Partner DIN 09256562
DIN 09256562 First appointment Jul 2021 Primary industry Business Services
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Jul 2021
Shareholding value β€’β€’β€’β€’ Premium profile

About Dhruv Nileshbhai Patvana

Data last updated:

Dhruv Nileshbhai Patvana is a Designated Partner at Aagney Pharmaceuticals Llp (since 2021). The company operates in Business Services.

DIN 09256562
Primary Designation Designated Partner
Industry Business Services
First Appointment 27 Jul 2021
Oldest Company Age 5 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Designated Partner27 Jul 20212021Active

Board colleagues of Dhruv Nileshbhai Patvana

NameDINCompanyDesignation
Mayankkumar Maheshbhai Akbari09256561Aagney Pharmaceuticals LlpDesignated Partner

Directorship timeline

Open interactive timeline →
Aagney Pharmaceuticals Llp
Premium access

Shareholding and investment profile for Dhruv Nileshbhai Patvana

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Dhruv Nileshbhai Patvana

Dhruv Nileshbhai Patvana currently holds 1 directorship: Aagney Pharmaceuticals Llp (Designated Partner, since 27 Jul 2021).

Dhruv Nileshbhai Patvana was first appointed on 27 Jul 2021 as Designated Partner at Aagney Pharmaceuticals Llp.

The current boards of Dhruv Nileshbhai Patvana's companies include Mayankkumar Maheshbhai Akbari (Aagney Pharmaceuticals Llp).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available